IGF1 and amyotrophic lateral sclerosis: Interestingly, it has been recently reported that skeletal muscle fiber production of IGF-1 is impaired in ALS patients (Lunetta et al., 2012), so that the modest effects found in some of the patients enrolled in the clinical trials might have been due to a compensation of impaired IGF-1 production by the exogenous administration of the factor.